| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
5,280,000 |
| Market
Cap: |
346.21(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$22 - $102.05 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Monopar Therapeutics is a biopharmaceutical company focused on developing proprietary therapeutics for cancer patients. Co.'s compounds in development: Validive®, a Phase 2b/3 clinical stage, mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a Phase 1b clinical stage analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart; MNPR-101, a preclinical stage uPAR-targeted antibody being developed as a radioimmunotherapeutic and companion diagnostic for cancers and COVID-19; and an early stage camsirubicin analog, MNPR-202, for various cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
130,058 |
| Total Buy Value |
$0 |
$0 |
$0 |
$125,188 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
11 |
| Total Shares Sold |
5,121 |
597,854 |
631,188 |
631,188 |
| Total Sell Value |
$343,889 |
$37,044,057 |
$38,210,747 |
$38,210,747 |
| Total People Sold |
1 |
5 |
5 |
5 |
| Total Sell Transactions |
1 |
5 |
6 |
6 |
| End Date |
2025-09-28 |
2025-06-27 |
2024-12-27 |
2023-12-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Vu Quan Anh |
Chief Financial Officer |
|
2025-12-26 |
4 |
B |
$69.95 |
$104,925 |
D/D |
1,500 |
1,500 |
2.74 |
- |
|
Klausner Arthur J |
Director |
|
2025-12-18 |
4 |
S |
$67.06 |
$343,889 |
D/D |
(5,121) |
8,762 |
|
-4% |
|
Klausner Arthur J |
Director |
|
2025-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
7,710 |
13,883 |
|
- |
|
Hendricks Diane |
10% Owner |
|
2025-12-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(43,499) |
567,580 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2025-09-30 |
4 |
D |
$81.67 |
$216,099 |
D/D |
(2,646) |
79,552 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2025-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,726 |
82,198 |
|
- |
|
Cittadine Andrew |
Chief Operating Officer |
|
2025-09-30 |
4 |
D |
$81.67 |
$154,846 |
D/D |
(1,896) |
48,289 |
|
- |
|
Cittadine Andrew |
Chief Operating Officer |
|
2025-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,327 |
50,185 |
|
- |
|
Mazar Andrew Paul |
Chief Executive OfficerMember |
|
2025-09-24 |
4 |
S |
$63.61 |
$34,999,957 |
D/D |
(550,229) |
272,026 |
|
6% |
|
Starr Christopher M |
Director |
|
2025-07-14 |
4 |
S |
$40.00 |
$672,020 |
D/D |
(16,800) |
5,173 |
|
-84% |
|
Starr Christopher M |
Director |
|
2025-07-14 |
4 |
OE |
$0.01 |
$84 |
D/D |
16,800 |
21,973 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2025-07-14 |
4 |
S |
$40.00 |
$672,020 |
D/D |
(16,800) |
73,472 |
|
-84% |
|
Robinson Chandler |
Chief Executive Officer |
|
2025-07-14 |
4 |
OE |
$0.01 |
$84 |
D/D |
16,800 |
90,272 |
|
- |
|
Tsuchimoto Kim R |
Director |
|
2025-07-14 |
4 |
S |
$40.00 |
$356,171 |
D/D |
(8,904) |
11,486 |
|
-84% |
|
Tsuchimoto Kim R |
Director |
|
2025-07-14 |
4 |
OE |
$0.01 |
$45 |
D/D |
8,904 |
20,390 |
|
- |
|
Cittadine Andrew |
Chief Operating Officer |
|
2025-06-30 |
4 |
D |
$35.78 |
$106,982 |
D/D |
(2,990) |
45,858 |
|
- |
|
Cittadine Andrew |
Chief Operating Officer |
|
2025-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,863 |
48,848 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2025-06-30 |
4 |
D |
$35.78 |
$209,850 |
D/D |
(5,865) |
73,472 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2025-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,344 |
79,337 |
|
- |
|
Mazar Andrew Paul |
Chief Executive OfficerMember |
|
2025-04-02 |
4 |
S |
$35.00 |
$1,166,690 |
D/D |
(33,334) |
822,255 |
|
7% |
|
Robinson Chandler |
Chief Executive Officer |
|
2025-03-31 |
4 |
D |
$36.41 |
$43,838 |
D/D |
(1,204) |
65,993 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2025-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,106 |
67,197 |
|
- |
|
Cittadine Andrew |
Chief Operating Officer |
|
2025-03-31 |
4 |
D |
$36.41 |
$27,089 |
D/D |
(744) |
41,985 |
|
- |
|
Cittadine Andrew |
Chief Operating Officer |
|
2025-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,791 |
42,729 |
|
- |
|
Robinson Chandler |
Chief Executive Officer |
|
2025-03-04 |
4 |
D |
$31.70 |
$55,760 |
D/D |
(1,759) |
63,091 |
|
- |
|
209 Records found
|
|
Page 1 of 9 |
|
|